The Expression of Soluble and Active Recombinant Haemophilus influenzae IgA1 Protease in E. coli by Long, Shinong et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 253983, 9 pages
doi:10.1155/2010/253983
Research Article
The Expression of Soluble and Active Recombinant
Haemophilusinfluenzae IgA1 Protease in E.coli
ShinongLong,ElainePhan,andMichelC.Vellard
Department of Cellular and Molecular Biology, BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949, USA
Correspondence should be addressed to Shinong Long, slong@bmrn.com
Received 9 August 2010; Accepted 4 October 2010
Academic Editor: Lori Snyder
Copyright © 2010 Shinong Long et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Immunoglobulin A1 (IgA1) proteases from Haemophilus inﬂuenzae are extracellular proteases that speciﬁcally cleave the hinge
region of human IgA1, the predominant class of immunoglobulin present on mucosal membranes. The IgA1 proteases may
have the potential to cleave IgA1 complexes in the kidney and be a therapeutic agent for IgA1 nephropathy (IgAN), a disease
characterized by deposition of the IgA1 antibody in the glomerulus. We have screened for the expression of recombinant H.
inﬂuenzae IgA1 protease by combining various expression plasmids, IgA1 protease constructs, and E. coli strains under multiple
conditions. Using the method we have developed, approximately 20–40mg/L of soluble and active H. inﬂuenzae IgA1 protease can
be produced from E. coli strain C41(DE3), a signiﬁcant increase in yield compared to the yield upon expression in H. inﬂuenzae
or other related bacteria.
1.Introduction
Immunoglobulin A1 (IgA1) proteases from bacteria, such
as Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus
inﬂuenzae, Streptococcus pneumoniae, Streptococcus sanguis,
Streptococcus oralis, Streptococcus mitis, Clostridium ramo-
sum, Prevotella melaninogenica, and other bacterial strains
areagroupofproteasesthatspeciﬁcallycleavetheIgA1hinge
region of human IgA1 and some great apes. IgA1 proteases
neither cleave human IgA2, IgG, and IgM nor do they cleave
IgA from mice, rat, or even monkey [1–3]. The C. ramosum
IgA protease, in addition, cleaves human IgA2m(1) allotype
[4]. In addition to the IgA1 hinge length and composition
[5–7], structures in the Fc region [8] and diﬀerent sites in
the CH3 domain [9] of IgA1 are required for cleavage.
IgA1 proteases are comprised of at least three families
having diﬀerent structural forms including serine-, metallo-,
and cysteine-type proteases. The serine type IgA1 proteases
are expressed as a precursor protein comprising a signal
peptide, an IgA1 protease domain, and a C-terminal α
protein and β-core domain. The C-terminal β-core domain
targets the protein to the cell membrane and facilitates
secretion of a α protein-protease domain polypeptide. The
β domain and α protein are cleaved from the precursor
polypeptide leaving the protease domain as the mature
protease. The metallo-type IgA1 proteases comprise a signal
sequenceandpropeptidewhichaidsinanchoringthepeptide
to the cell membrane and contains several sites for metal ion
(e.g., zinc) binding in the protease domain. The structure
for the cysteine-type IgA1 protease has yet to be determined.
The IgA1 proteases of H. inﬂuenzae and Neisseria species are
of the serine type. For serine type IgA1 proteases, cleavage
between proline and serine is designated as type 1 whereas
cleavage between proline and threonine is designated as type
2. Those IgA1 proteases produced by streptococcal species
are of the metallo type; the C. ramosum IgA protease has a
unique sequence and is a diﬀerent type of metalloproteinase.
The cysteine types of IgA1 proteases are produced by
Prevotella species [4, 10–15].
IgA nephropathy (IgAN), a disease characterized by
deposition of the IgA1 antibody in the glomerulus, can
lead to kidney dysfunction and, in certain cases, kidney
failure [16]. Exogenous proteolytic enzymes have been tested
as therapy to treat IgA1 deposition in animal models in
an attempt to remove IgA1 deposits in the kidneys. The
administered proteases, chymopapain and subtilisin, act by
proteolytic cleavage of IgA1 deposits in the kidney but are
not speciﬁc for IgA1 molecules and digest a variety of other2 Journal of Biomedicine and Biotechnology
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Figure 1: IgA1 protease expression constructs. Only the IgA1 protease domains with or without the signal peptide were cloned into pET21a
and pCold IV expression vectors. S: signal peptide for targeting to the periplasm; a, b, c: the three IgA1 protease self-cleavage sites delineating
the diﬀerent domains.
proteins [17, 18]. The IgA1-speciﬁc IgA1 protease from H.
inﬂuenzae has been used to treat IgAN in animal models.
The H. inﬂuenzae IgA1 protease reduced the deposition of
glomerular IgA1 immune complexes in a passive mouse
model [19]. IgA1 protease may have potential as a therapeu-
tic agent for IgAN.
Production of IgA1 protease in amounts suﬃcient for
therapeutic use has not been achieved due to the low
naturalproductionoftheproteininnaturallyproducingcells
such as H. inﬂuenzae, N. gonorrhoeae, and N. meningitidis.
Moreover, H. inﬂuenzae, N. gonorrhoeae, and N. meningitidis
are pathogenic bacterial species, and H. inﬂuenzae requires
hemin for growth which makes it impractical for production
of IgA1 proteases at a large scale. The soluble and active
IgA1 proteases from S. pneumoniae, S. suis, and C. ramosum
have been expressed in E. coli at a low yield [4, 20, 21].
We report here a method of expressing only the protease
domain (without α protein and β-core domain) of H.
inﬂuenzae IgA1proteaseinE.coli,whereintheyieldandtotal
recovery of soluble and active recombinant IgA1 protease are
signiﬁcantly increased compared to previous methods.
2.MaterialsandMethods
2.1. Cloning of IgA1 Protease into Expression Vectors. IgA1
protease-encoding DNA fragments were ampliﬁed from
pFG26 plasmid (from Jiazhou Qiu and Andrew G. Plaut
of Tufts Medical Center, containing full-length wild-type
H. inﬂuenzae IgA protease gene, GenBank: X59800) by
PCR using diﬀerent pair of primers (Figure 1 and Table 1).
Ampliﬁed PCR fragments were digested with Nde I and
BamHI and cloned into pET21a (Novagen) and pColdIV
(Takara) vectors (Table 1).
2.2. Expression of IgA1 Protease in E. coli. Bacterial strains
[BL21(DE3), BL21(DE3)pLysS, ArcticExpress(DE3)
(Stratagene); BL21(DE3)pGro7 (Takara); C41(DE3),
C43(DE3), C41(DE3)pLysS, C43(DE3)pLysS (Lucigen);
Origami B(DE3), Origami B(DE3)pLysS, Tuner(DE3)
(Novagen); KRX (Promega)] containing plasmids (pET-
IGAN, pET-S-IGAN, pCold-IGAN, or pCold-S-IGAN)
were cultured in 4ml LB medium containing 100μg/ml of
carbenicillin at 37◦C with shaking. When OD600 of bacterial
culture reached 0.6, IPTG was added to a ﬁnal concentration
of 0.2–1mM and incubated at 12◦C–30◦C for 3–24 hours
with shaking. Bacterial cell pellets were collected by
centrifugation at 5000rpm and 4◦C for 10 minutes and lysed
with 1ml B-PER II Bacterial Extraction Reagent (Thermo)
with Benzonase Nuclease (Novagen). The total cell lysates
were centrifuged at 14000rpm and 4◦C for 15 minutes. The
supernatants were assayed for protein concentration with
BCA protein Assay Reagent (Thermo) and adjusted to have
the same total protein concentration with B-PER II.
2.3. Immunodetection of IgA1 Protease Expression. Total cell
lysates or soluble supernatants were separated by SDS-
PAGE (reducedgel)and electrotransferredtoa nitrocellulose
membrane with iBlot (Invitrogen). The membrane was
blocked with 5% non-fat milk powder in TBS-T buﬀer (TBS
containing 0.05% Tween 20) and incubated with rabbit anti-
his polyclonal Ab (Abcam, 0.4μg / m l )a tR Tf o r2h o u r s .
The membrane was washed three times with TBS-T buﬀer
and incubated with AP-conjugated antirabbit IgG (Promega,
0.2μg/ml) at RT for 1 hour. The membrane was washed
three times with TBS buﬀer, and the expressed proteins were
visualized by adding 10ml Western Blue Stabilized Substrate
(Promega).
2.4. IgA1 Protease Activity Assay. The activity of IgA1
proteases from cell lysates and supernatants was determined
by Western blotting. The positive control (puriﬁed IgA1
protease from H. inﬂuenzae, supplied by Jiazhou Qiu and
Andrew G. Plaut of Tufts Medical Center) and negative
controls as well as 10μlo fc e l ll y s a t e so rs o l u b l es u p e r n a t a n t s
were added to 10μl of human IgA1 (1mg/ml, supplied
by CalBiochem and Paul Fitzpatrick of BioMarin), mixed
well and incubated at 37◦C overnight. The samples were
separated by SDS-PAGE (reduced gel) and electrotransferredJournal of Biomedicine and Biotechnology 3
Table 1: IgA1 protease expression constructs.
Construct Vector Primer Tag Expression location
pET-S-IGAN pET21a
IgA-NdeI-SS-5
 :
C-terminal His tag E. coli periplasm
gctcatatgctaaataaaaaattcaaactc
IgA-6his-BamHI-3
 :
caaggatcctagtggtggtggtggtggt
gaggcacatcagcttgaatattattag
pET-IGAN pET21a
IgA-NdeI-5
 :
C-terminal His tag E. coli cytoplasm
gctcatatggcgttagtgagagacgatgtg
IgA-6his-BamHI-3
 :
caaggatcctagtggtggtggtggtggt
gaggcacatcagcttgaatattattag
pCold-S-IGAN pCold IV
IgA-NdeI-SS-5
 :
C-terminal His tag E. coli periplasm
gctcatatgctaaataaaaaattcaaactc
IgA-6his-BamHI-3
 :
caaggatcctagtggtggtggtggtggt
gaggcacatcagcttgaatattattag
pCold-IGAN pCold IV
IgA-NdeI-5
 :
C-terminal His tag E. coli cytoplasm
gctcatatggcgttagtgagagacgatgtg
IgA-6his-BamHI-3
 :
caaggatcctagtggtggtggtggtggt
gaggcacatcagcttgaatattattag
to a nitrocellulose membrane with iBlot (Invitrogen). The
membrane was blocked with 5% non-fat milk powder
in TBS-T buﬀer (TBS containing 0.05% Tween 20) and
incubated with mouse anti-IgA-Fab mAb (CalBiochem,
0.4μg/ml) at RT with shaking for 2 hours. The membrane
was washed three times with TBS-T buﬀer and incubated
with AP-conjugated antimouse IgG (Promega, 0.2μg/ml) at
RT with shaking for 1 hour. The membrane was washed
three times with TBS buﬀer, and the expressed proteins were
visualized by adding 10ml Western Blue Stabilized Substrate
(Promega).
The activity of puriﬁed IgA1 protease was analyzed
with an Experion automated electrophoresis system (Bio-
Rad). Eight μL of puriﬁed IgA1 (1600ng/μL) was added
to a PCR tube containing 1μL of IgA1 protease sample,
and the resulting mixture was incubated in a heat block at
37◦C for 1min. The reaction was stopped by the addition
of 5μLo fs a m p l eb u ﬀer to the reaction tube followed by
vortexing. Standard samples were prepared by the addition
of 5μLo fs a m p l eb u ﬀer to tubes containing 9μL of standard
IgA1 (1600, 400, 100, 25, and 0ng/μL). The samples were
heated at 95–100◦C for 3–5min and centrifuged brieﬂy. Two
hundred and ten μl of deionized water (0.2 micron-ﬁltered,
not autoclaved) was added to the samples and mixed well by
vortexing. The proteolytic activity of the IgA1 protease was
measured as the decrease in IgA1 concentration per minute
(ng/μL/min/ng of IgA1 protease).
2.5. Screening Soluble IgA1 Protease Expression Levels with
ELISA. One hundred μl of cell lysate supernatant, as well as
IgA1 protease control, was added to the wells of an ELISA
plate (Nunc Maxisorp) and incubated overnight at 4◦C. The
plate was washed 3 times with PBST (PBS + 0.05% Tween-
20) and blocked with Blocking Buﬀer (PBST + 3% BSA)
at RT for 1-2hr. Following the incubation, the plate was
washed3timesagainwithPBSTandincubatedwith100μlof
rabbit anti-His polyclonal Ab (Abcam, 0.4μg/ml) at RT with
shaking for 2 hours. The plate was then washed 3 times with
PBST buﬀer and incubated with 100μl of HRP-conjugated
antirabbit IgG H&L (Abcam, 0.1μg/ml) at RT with shaking
for 1 hour. Finally, the plate was washed 4 times with PTBST
buﬀer. The 1-Step Turbo TMB-ELISA solution (Pierce) was
added to the wells and incubated in the dark for 5 to 30
minutes.Stopsolution(1-2Msulfuricacid)wasaddedtothe
wells to stop the reaction, and the OD450 was measured with
a plate reader.
2.6. Puriﬁcation of IgA1 Protease from E. coli C41 (DE3). The
cell pellet was suspended in TBS buﬀer and homogenized
by a high-pressure homogenizer. The homogenized samples
were centrifuged at 12,000rpm for 30 minutes at 4◦C,
and the supernatant was ﬁltered through a Sartorius ﬁlter.
The ﬁltered crude IgA1 protease was loaded onto the
nickel column (IMAC Chelating Sepharose, GE Healthcare,
charged with nickel sulfate). The bound protein was eluted
by an imidazole gradient. The eluate fractions from the
nickel column were diluted 10-fold with 25mM tris, pH
8.0, and loaded onto the Q sepharose column (Q sepharose
FF, GE Healthcare). The unbound ﬂow through fraction
was concentrated by tangential ﬂow ﬁltration (Vivaﬂow200,
30kDa PES, Sartorius) and loaded onto a S300 SEC column
(S300 Sephacryl HR-GE Healthcare).4 Journal of Biomedicine and Biotechnology
14
19
28
39
51
64
97
191
(kDa)
P
r
o
t
e
i
n
m
a
r
k
e
r
U
n
-
i
n
d
u
c
e
d
p
E
T
-
I
G
A
N
#
1
c
e
l
l
l
y
s
a
t
e
U
n
-
i
n
d
u
c
e
d
p
E
T
-
I
G
A
N
#
1
s
u
p
e
r
n
a
t
a
n
t
p
E
T
-
I
G
A
N
#
1
c
e
l
l
l
y
s
a
t
e
p
E
T
-
I
G
A
N
#
1
s
u
p
e
r
n
a
t
a
n
t
p
E
T
-
I
G
A
N
#
2
c
e
l
l
l
y
s
a
t
e
p
E
T
-
I
G
A
N
#
2
s
u
p
e
r
n
a
t
a
n
t
p
E
T
-
S
-
I
G
A
N
#
1
c
e
l
l
l
y
s
a
t
e
p
E
T
-
S
-
I
G
A
N
#
1
s
u
p
e
r
n
a
t
a
n
t
p
E
T
-
S
-
I
G
A
N
#
2
c
e
l
l
l
y
s
a
t
e
p
E
T
-
S
-
I
G
A
N
#
2
s
u
p
e
r
n
a
t
a
n
t
(a) Coomassie blue stain
IgA1
protease
P
r
o
t
e
i
n
m
a
r
k
e
r
U
n
-
i
n
d
u
c
e
d
p
E
T
-
I
G
A
N
#
1
c
e
l
l
l
y
s
a
t
e
U
n
-
i
n
d
u
c
e
d
p
E
T
-
I
G
A
N
#
1
s
u
p
e
r
n
a
t
a
n
t
p
E
T
-
I
G
A
N
#
1
c
e
l
l
l
y
s
a
t
e
p
E
T
-
I
G
A
N
#
1
s
u
p
e
r
n
a
t
a
n
t
p
E
T
-
I
G
A
N
#
2
c
e
l
l
l
y
s
a
t
e
p
E
T
-
I
G
A
N
#
2
s
u
p
e
r
n
a
t
a
n
t
p
E
T
-
S
-
I
G
A
N
#
1
c
e
l
l
l
y
s
a
t
e
p
E
T
-
S
-
I
G
A
N
#
1
s
u
p
e
r
n
a
t
a
n
t
p
E
T
-
S
-
I
G
A
N
#
2
c
e
l
l
l
y
s
a
t
e
p
E
T
-
S
-
I
G
A
N
#
2
s
u
p
e
r
n
a
t
a
n
t
(b) Western blot with anti-His Ab
Figure 2: pET-S-IGAN and pET-IGAN IgA1 proteases were expressed in E. coli as inclusion bodies. The expressions of pET-S-IGAN and
pET-IGAN were induced in BL21 (DE3) cells with 1mM IPTG at 30◦C for 3 hours. The total cell lysates and soluble supernatants were
analyzed with SDS-PAGE (reduced condition) and Western blot.
3. Results
3.1. Expression of IgA1 Proteases in E. coli. The serine-type
IgA1 protease is initially translated as a precursor composed
of four functional domains: (i) an amino terminal signal
peptide to target it through the inner membrane to the
periplasm; (ii) the mature protease domain; (iii) the α-
p r o t e i nd o m a i n ,a n d( i v )t h eβ-core domain for transport
across the outer membrane. The β-core domain integrates
into the outer membrane and forms a pore structure that
the mature protease domain and the α-protein domain are
translocated through the β-core domain channel into the
extracellular space. The mature IgA1 protease is released by
self-cleavage at three cleavage sites: a, b, and c (Figure 1)
[10, 22, 23]. In here, only the mature protease domain with
or without signal peptide was cloned and expressed in E.
coli. The C-terminal His-tagged IgA1 protease domain with
the signal peptide (S) was ampliﬁed by PCR and cloned
into pET21a expression vector (using T7 promoter) and
pCold IV expression vector (using cold shock promoter,
expression occurs at low temperature) (pET-S-IGAN and
pCold-S-IGAN) for periplasmic expression. The C-terminal
His-tagged IgA1 protease domain only was also ampliﬁed
by PCR and cloned into pET21a and pCold IV vectors
(pET-IGAN and pCold-IGAN) for cytoplasmic expression
(Figure 1 and Table 1). pET-S-IGAN and pET-IGAN were
ﬁrst expressed in BL21(DE3) cells induced with 1mM IPTG
at 30◦C for 3 hours. The majority of IgA1 proteases were
detected in total cell lysates which are shown as a band with
molecular weight around 100kDa (Figure 2, Lanes 3, 5, 7,
and 9) rather than the cell supernatants (Figure 2,L a n e s
4, 6, 8, and 10) indicating that both constructs resulted in
expression of IgA1 proteases as inclusion bodies.
When the expression of pET-S-IGAN and pET-IGAN
was induced at low temperature (12◦C) and a low concentra-
tion of IPTG (0.4mM) in diﬀerent cell strains (BL21(DE3),
C41(DE3), C43(DE3), BL21(DE3)pGro7, and Origami
B(DE3),OrigamiB(DE3)pLysS),smallfractionsofexpressed
IgA proteases were soluble, as evidenced by the detection
of IgA1 protease in the cell supernatant (data not shown).
When the expression of pCold-S-IGAN and pCold-IGAN
was induced at low temperature (12◦C) and low concentra-
tion of IPTG (0.4mM) in diﬀerent cell strains (BL21(DE3),
C41(DE3), C43(DE3), BL21(DE3)pLysS, Origami B(DE3),
and BL21(DE3)pGro7), all expressed IgA1 proteases were
soluble (Figure 3).
The expressed IgA1 proteases from the four constructs
described above expressed in diﬀerent E. coli cells were
tested for IgA1 cleavage activity by Western blotting. All
IgA1 proteases expressed in the above assays exhibited IgA1Journal of Biomedicine and Biotechnology 5
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(b) Western blot with anti-His Ab
Figure 3:pCold-IGANIgA1proteaseswereexpressedassolubleproteinsinE.coli.TheexpressionsofpCold-IGANcellstrainswereinduced
at 12◦C with 0.4mM IPTG for 18 hours. The cell pellets were lysed and centrifuged. The total cell lysates and soluble supernatants were
analyzed with SDS-PAGE (reduced condition) and Western blot.
cleavageactivity(Figure 4).Thehighmolecularweightbands
in Figure 4 lanes 7 and 9 may indicate cross-reactivity of the
anti-IgA detecting antibody with the IgA1 protease itself.
3.2. Screening Soluble IgA1 Protease Expression Levels with
ELISA. ELISA was used to quantify expression levels of
IgA1 protease expressed by all four IgA protease con-
structs described above (pET-S-IGAN, pET-IGAN, pCold-
S-IGAN, and pCold-IGAN), whose expression was induced
at low temperature (12◦C) and low concentration of IPTG
(0.4mM) in various cell strains. The pET-IGAN construct
resulted in the production of higher levels of soluble IgA1
protease in several cell strains (Table 2, in bold italic font).
We then tested the expression of pET-IGAN induced at
various temperatures and concentrations of IPTG and in
various cell strains. Overall, greater amounts of soluble IgA1
protease were produced at 20◦C with 0.4mM IPTG in most
cell strains. The C41 (DE3) strain produced the highest titer
of protease under the same conditions compared with other
E. coli strains used for recombinant expression (Table 2,i n
bold font). Finally, the best condition for producing soluble
IgA1 protease in C41 (DE3) was screened by ELISA again.
The C41 (DE3) E. coli strain containing pET-IGAN plasmid
produced the highest level of soluble IgA1 protease when
induced with 0.4mM IPTG at 20◦Cf o r2 4h o u r s( Table 2,
in italic font). And the expressed soluble IgA1 protease in
C41 (DE3) was conﬁrmed to have correct molecular weight
(∼100kDa) (Figure 5) and proteolytic activity (data not
shown).
3.3.CharacterizationofIgA1Proteases. ThesolubleIgA1pro-
tease was produced from E. coli strain C41 (DE3) containing
pET-IGAN plasmid with 0.4mM IPTG induction at 20◦C.
The soluble IgA1 protease was puriﬁed by a nickel column
and further puriﬁed by an anion-exchange column and a
size-exclusion column to more than 95% pure (Figure 6,
Lane 2: C41 IgA1 protease). The ﬁnal yield of puriﬁed IgA1
protease was 20–40mg/L from approximately 100mg/L of
total soluble expressed IgA1 protease. We have developed
a novel IgA1 protease activity assay using an Experion
automated electrophoresis system. The proteolytic activity
of the IgA1 protease was measured as the decrease in IgA1
concentration per minute (ng/μL/min/ng of IgA1 protease).
Using the method we developed, the average activities of
puriﬁed IgA1 protease from E. coli C41 (DE3) and IgA1
protease from H. inﬂuenzae (from Jiazhou Qiu and Andrew
G. Plaut of Tufts Medical Center) were approximately 46 and
27ng/μL/min per ng of IgA1 protease, respectively. The IgA1
protease produced from H. inﬂuenzae showed lower activity
in this experiment probably due to impurity or degradation
of the H. inﬂuenzae IgA1 protease sample (Figure 6, the
extra low molecular weight band in the ﬁrst line: HI IgA1
protease).
4. Discussion
The serine-type IgA1 protease precursor is composed of
four domains: signal peptide, protease domain, α-protein
domain, and β-core domain. The previous attempts to6 Journal of Biomedicine and Biotechnology
Table 2: Screening the expression of soluble IgA1 proteases by ELISA.
Expression level (OD450)
First round screening Second round screening Third round screening
Control
Negative control:
C41(DE3) supernatant
0.08
Positivecontrol:
puriﬁedIgA1protease
0.21 Positive control:
puriﬁed IgA1 protease
0.20
Negative control:
BL21(DE3)
supernatant
0.10
Negative control:
BL21(DE3)
supernatant
0.08
Construct
C41(DE3) 1.13 0.4mM IPTG,12◦C 0.72 15◦C, 0.2mM IPTG 0.57
15◦C, 0.4mM IPTG 0.72
0.4mM IPTG,20◦C 1.10 15◦C, 0.6mM IPTG 0.54
20◦C, 0.2mM IPTG 0.87
1mMIPTG,12 ◦C 0.66 20◦C, 0.4mM IPTG 1.17
20◦C, 0.6mM IPTG 1.02
1mMIPTG,20 ◦C 1.01 26◦C, 0.2mM IPTG 0.57
26◦C, 0.4mM IPTG 0.51
26◦C, 0.6mM IPTG 0.33
Origami B(DE3) 0.98 0.4mM IPTG,12◦C 0.36
0.4mM IPTG,20◦C 0.29
1mMIPTG,12 ◦C 0.35
1mMIPTG,20 ◦C 0.29
BL21(DE3) 0.93 0.4mM IPTG,12◦C 0.54
0.4mM IPTG,20◦C 0.59
pET-IGAN 1mMIPTG,12 ◦C 0.49
1mMIPTG,20 ◦C 0.61
Tuner (DE3) 0.92 0.4mM IPTG,12◦C 0.48
0.4mM IPTG,20◦C 0.67
1mMIPTG,12 ◦C 0.46
1mMIPTG,20 ◦C 0.57
BL21(DE3)pGro7 1.01 0.4mM IPTG,12◦C 0.54
0.4mM IPTG,20◦C 0.73
1mMIPTG,12 ◦C 0.61
1mMIPTG,20 ◦C 0.47
ArcticExpress (DE3) 1.00 0.4mM IPTG,12◦C 0.68
0.4mM IPTG,20◦C 0.98
1mMIPTG,12 ◦C 0.70
1mMIPTG,20 ◦C 0.89
KRX 0.56
Origami B(DE3)pLysS 0.75
C43 (DE3) 0.14Journal of Biomedicine and Biotechnology 7
Table 2: Continued.
Expression level (OD450)
First round screening Second round screening Third round screening
pET-S-IGAN
BL21(DE3) 0.90
C41(DE3) 0.83
C43(DE3) 0.20
Origami B(DE3) 0.82
KRX 0.73
ArcticExpress(DE3) 0.85
BL21(DE3)pGro7 0.86
Tuner (DE3) 0.82
pCold-S-IGAN
BL21(DE3) 0.76
C41(DE3) 0.70
C43(DE3) 0.79
Origami B(DE3) 0.70
BL21(DE3)pGro7 0.44
pCold-IGAN
BL21(DE3) 0.56
C41(DE3) 0.68
C43(DE3) 0.15
Origami B(DE3) 0.24
BL21(DE3)pGro7 0.28
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Figure 4: Expressed soluble IgA1 proteases were active. IgA1 was incubated with cell lysates or soluble supernatant at 37◦C overnight.
SDS-PAGE (reduced condition) and Western blotting with anti-IgA Ab were employed to detect the cleavage. IgA1 was cleaved by soluble
supernatant (or cell lysate) induced at 12◦C with 0.4mM IPTG (except some were induced at 37◦C with 1mM IPTG for 3 hours).8 Journal of Biomedicine and Biotechnology
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Figure 5: Expression of soluble IgA1 protease from pET-IGAN
in C41 (DE3) strain. SDS-PAGE (reduced condition) and Western
blotting with anti-His Ab were employed to conﬁrm the expression
of IgA1 protease. Negative control: un-induced pET-IGAN C41
(DE3) soluble supernatant; puriﬁed IgA1 protease: puriﬁed IgA1
protease from H. inﬂuenzae.
produce natural IgA1 proteases from H. inﬂuenzae, N.
gonorrhoeae, and N. meningitides resulted in a very low
titer of total IgA1 proteases. Moreover, the yield of puriﬁed
IgA1 proteases directly from the cell culture media was low
(0.03 and <0.007mg/L) [23, 24]. It has been reported that
IgA1 proteases are capable of being expressed in E. coli
as inclusion bodies or being secreted to the media with
reduced activity, or no activity, or in low yield of recov-
ered recombinant IgA1 proteases [25–27]. Unlike previous
attempts to express recombinant, full-length IgA1 protease
precursor in E. coli, our approach was to screen four IgA1
protease constructs (pET-S-IGAN, pET-IGAN, pCold-S-
IGAN,andpCold-IGAN)encodingpolypeptidescomprising
the protease domain only (and lacking the α protein and β-
core domains) in various E. coli strains. Various conditions
for the expression of soluble and active IgA1 proteases were
used. Our results demonstrated that all four IgA1 protease
constructs were able to produce soluble and active IgA1
proteases in several E. coli strains when induced at low
temperature and low concentration of IPTG. ELISA as well
as activity assay showed that soluble, active IgA1 proteases
were expressed in several E. coli strains over a range of
culture temperatures and IPTG culture concentration. C41
(DE3) cells transformed with the pET-IGAN construct had
the highest titer (approximately 100mg/L) when induced
with 0.4mM IPTG at 20◦C. The titer is much higher than
the previous report in which it has up to around 2mg/L
[23]. It is possible that the present methods can produce
signiﬁcant amounts of soluble and active IgA1 proteases
because the host cells (e.g., E. coli) express only the protease
domain and not the full-length precursor protein. Thus, the
expressed polypeptide does not need to be cleaved into the
matureprotease,unlike previousrecombinantexpressions in
H. inﬂuenzae and other bacteria. Because the IgA1 protease
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Figure 6: Characterization of puriﬁed IgA1 proteases from E. coli
C41 (DE3) and H. inﬂuenzae. SDS-PAGE and Coomassie blue stain
(reduced condition). HI IgA1 protease: Puriﬁed IgA1 protease from
H.inﬂuenzae;C41IgA1protease:puriﬁedIgA1proteasefromE.coli
C41 (DE3).
was expressed as a C-terminal his-tagged form, it was easily
puriﬁedwithmuchhigheryield(20–40mg/L),whichismore
than 1000-folds than the highest yield from previous report
(0.03mg/L) [23].
We report, for the ﬁrst time, the expression of only
the IgA1 protease proteolytic domain without the α protein
domain or the β-core domain, for recombinant production
of soluble and active IgA1 proteases. The protease domain
alone was conﬁrmed to have full protease activity. Under
optimized conditions, it was also expressed as soluble and
active form in E. coli. This method uses E. coli instead of
pathogenic bacteria such as H. inﬂuenzae, N gonorrhoeae,
and N. meningitides. In addition, the signiﬁcantly increased
yield of the IgA1 proteases using the current method allows
for production of the IgA1 proteases in amounts useful for
administration to treat IgA nephropathy and other IgA1
deposition diseases.
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